find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Leukemia
Phase III
Accepting Patients
nct/study# NCT04468984 / M20-178
Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT04472598 / M16-191
Abbvie, Protocol: M16-191, PI: Dr. Mccloskey, Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT03555955 / CPX351-102
A Phase 1 Trial To Evaluate The Potential Impact Of Renal Impairment On The Pharmacokinetics And Safety Of CPX-351 (Daunorubicin And Cytarabine) Liposome For Injection Treatment In Adult Patients With Hematologic Malignancies
Learn More
Leukemia
NA
Accepting Patients
Leukemia
NA
Accepting Patients
nct/study# NCT01688011 / AZA-MDS-006
Connect MDS And AML: The Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia (AML) Disease Registry
Learn More
Leukemia
Phase II
Active
nct/study# NA / SY-1425-202
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen.
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.